Table of Content

25 April 2024, Volume 16 Issue 2 Previous Issue    Next Issue

Select

Expert Consensus on detection and clinical application of tumor DNA methylation markers (Version 2024) Tumor marker committee of Chinese anti?cancer association 2024, 16 (2):  129-142.  doi: 10.3969/j.issn.1674-5671.2024.02.01 Abstract ( 868 )   PDF   Save Related Articles | Metrics

Select

Application status and challenges of artificial intelligence in digital pathology of renal cancer HOU Naiqiao, ZHAI Wei, ZHENG Junhua 2024, 16 (2):  143-151.  doi: 10.3969/j.issn.1674-5671.2024.02.02 Abstract ( 150 )   PDF   Save Related Articles | Metrics

Select

Survey and analysis of mutual recognition mechanism for ethical review of clinical trials of tumors in China WANG Yumeng, LIU Zhimin, ZHU Ji, YU Hongping, LI Jie, ZHAO Qing, WU Dawei, SUI Guangyi, ZHOU Ming, YAN Zhao 2024, 16 (2):  152-157.  doi: 10.3969/j.issn.1674-5671.2024.02.03 Abstract ( 136 )   PDF   Save Related Articles | Metrics

Select

A study on the mechanism of Bufotalin-induced ferroptosis in acute promyelocytic leukemia HL-60 cells WANG Rong, ZHOU Zhihui, LI Hong, LI Zihui 2024, 16 (2):  158-165.  doi: 10.3969/j.issn.1674-5671.2024.02.04 Abstract ( 155 )   PDF   Save Objective To investigate the effect and mechanism of Bufotalin on ferroptosis in acute promyelocytic leukemia (APL) HL⁃60 cells. Methods APL HL⁃60 cells were treated with Bufotalin at different concentrations (0.1, 0.5, 1.0, 2.0, and 4.0 μg·mL-1, respectively), and the morphological changes of cells were observed using a light microscope. The survival rate of cells was detected by the CCK⁃8 method. The expression levels of ferroptosis⁃related proteins CD71, xCT, FTH1 and GPX4 in HL⁃60 cells were detected by Western blot. The changes of contents of intracellular GSH and GSSG were detected by GSH/GSSG detection kit. The changes of contents of intracellular MDA in HL⁃60 cells were determined by MDA detection kit. HL⁃60 cells were treated with 0.5 μg·mL⁃1 Bufotalin 0.1 μmol·L⁃1 Fer⁃1 and  0.5 μg·mL⁃1 Bufotalint 0.1 μmol·L⁃1 Fer⁃1, respectively, and the morphological changes of cells were observed using a light microscope, the expression levels of ferroptosis⁃related proteins were detected by Western blot. Results After treatment with different concentrations of Bufotalin, HL⁃60 cells showed irregular shapes, such as dumbbell shape and spindle shape, and the survival rate of the cells decreased in a time⁃dose dependent relationship. Compared with the control group, Bufotalin could reduce the expression levels of ferroptosis⁃related proteins GPX4, xCT and FTH1, as well as the content of total glutathione (all P<0.01), and increase the expression level of CD71 protein and the content of MDA (all P<0.05). Compared with the control group, the growth number and morphology of HL⁃60 cells were not significantly changed after combined treatment of Bufotalin and Fer⁃1, the protein expression levels of CD71, xCT, FTH1 and GPX4 were not statistically significant (all P>0.05). Conclusions  Bufotalin can inhibit the proliferation of APL HL⁃60 cells and induce ferroptosis, the underlying molecular mechanism is probably realized through GPX4⁃mediated antioxidant pathway and iron metabolism pathway.  Related Articles | Metrics

Select

Inhibitory effect of oleanolic acid on liver cancer HCCLM3 cells transplanted tumor in nude mice and its mechanism YUAN Bin, HUANG Delun, ZHOU Fengling, YE Yixian, ZHOU Xiaoqi, WEI Yanfei 2024, 16 (2):  166-171.  doi: 10.3969/j.issn.1674-5671.2024.02.05 Abstract ( 140 )   PDF   Save Objective To investigate the effects of oleanolic acid on the growth of human liver cancer HCCLM3 cells transplanted tumor in nude mice, the apoptosis of tumor tissues and the expression of related genes. Methods Human liver cancer HCCLM3 cells were inoculated into the subcutaneous skin of BALB/c nude mice to construct liver cancer transplantation tumor model, and the nude mice were randomly divided into model group and drug group, which were given 0.01 mL/g corn oil and 5 mg/kg oleanolic acid by gavage, respectively. The general state, body weight, tumor weight and volume of nude mice in each group were measured and recorded during administration. The pathological changes of cell necrosis, cell proliferation and apoptosis in transplanted tumor tissues were detected by HE, Ki67 and TUNEL staining, respectively. The mRNA expression levels of CyclinD1, CyclinE1, CDK4, Bcl⁃2 and Bax genes in transplanted tumor tissues were detected by qRT⁃PCR. Results Compared with the model group, there was no significant effect on the body weight of nude mice in the drug group, while the weight and volume of transplanted tumor were significantly decreased (all P<0.05). HE staining showed that the morphology of transplanted tumor in the drug group changed significantly, and necrotic areas appeared. The positive expression intensity of Ki67 in tumor tissues of the drug group was significantly lower than that of the model group (P<0.01); the positive expression intensity of  TUNEL was significantly higher than that of the model group (P<0.05).The mRNA expression levels of proliferation⁃related genes CyclinD1, CyclinE1 and CDK4 in transplanted tumor tissues were decreased after oleanolic acid administration, but the differences were not statistically significant (all P>0.05); the mRNA expression level of anti⁃apoptosis⁃related gene Bcl⁃2 was decreased (P<0.05), while the mRNA expression level of pro⁃apoptosis⁃related gene Bax was increased (P<0.01). Conclusions Oleanolic acid can inhibit the growth of human liver cancer HCCLM3 cells transplanted tumors in nude mice, and its mechanism may be related to the inhibition of cell proliferation and the induction of apoptosis. Related Articles | Metrics

Select

Epidemiological characteristics and disease burden analysis of gastric cancer in Guangxi,2011—2018 QIN Liming, ZHOU Zihan, CAO Ji, LI Qiulin, YU Jiahua, RONG Minhua, ZHAO Libin, MAI Yuejiao, GE Lianying, QIN Yuzhou, YU Hongping 2024, 16 (2):  172-178.  doi: 10.3969/j.issn.1674-5671.2024.02.06 Abstract ( 162 )   PDF   Save Objective To analyze the temporal variation trend of the epidemiological characteristics and disease burden of gastric cancer in Guangxi from 2011 to 2018, providing a scientific basis for formulating effective prevention and control measures. Methods Based on the incidence and mortality data of gastric cancer in Guangxi from 2011 to 2018, the crude incidence rate, crude mortality rate, age⁃standardized incidence /mortality rate by Chinese standard population (ASIRC /ASMRC), and age⁃standardized incidence/mortality rate by world standard population (ASIRW/ASMRW) were calculated to analyze the epidemiological characteristics of gastric cancer in Guangxi from 2011 to 2018; the disability⁃adjusted life⁃years (DALYs), years of life lost (YLLs) due to premature death, and years lived with disability (YLDs) due to disease were calculated to evaluate the disease burden of gastric cancer in Guangxi from 2011 to 2018. The average annual percent change (AAPC) of the above indexes was calculated by using the Joinpoint regression model to analyze the temporal variation trend of epidemiological characteristics and disease burden of gastric cancer. Results From 2011 to 2018, the ASIRC of gastric cancer in Guangxi decreased from 13.33/105 in 2011 to 10.14/105 in 2018, showed a significant downward trend (AAPC=-4.06%, P=0.002); the ASMRC decreased from 9.87/105 in 2011 to 7.90/105 in 2018 (AAPC=-2.58%, P=0.006); the DALYs rate decreased from 161.10/105 in 2011 to 138.50/105 in 2018, but the trend of change was not statistically significant (AAPC=-0.79%, P=0.366). The ASIRC, ASMRC and DALYs rate of gastric cancer in male were higher than those in female from 2011 to 2018. The ASIRC and ASMRC of gastric cancer in male decreased at an average annual rate of 2.56% (AAPC=-2.56%, P=0.181) and 1.79% (AAPC=-1.79%, P=0.190), respectively, but the trends of change were not statistically significant. The ASIRC of gastric cancer in female changed at an average annual rate of 4.40% (AAPC=-4.40%, P=0.002), showed a significant downward trend, and the ASMRC decreased at an average annual rate of 3.17% (AAPC=-3.17%, P=0.065), but the trend of change was not statistically significant. Conclusions The incidence rate and mortality rate of gastric cancer in Guangxi show a downward trend from 2011 to 2018, but the disease burden of gastric cancer is still at a relatively high level. It is necessary to continuously strengthen the prevention and treatment of gastric cancer, with focus on screening and early diagnosis and treatment for high⁃risk groups of gastric cancer, to reduce the disease burden of gastric cancer. Related Articles | Metrics

Select

Trends in the incidence and mortality of liver cancer in China based on the JoinPoint regression model,2000—2019 WANG Juwei, WANG Jing, MA Lijun, LI Zan 2024, 16 (2):  180-185.  doi: 10.3969/j.issn.1674-5671.2024.02.07 Abstract ( 200 )   PDF   Save bjective To analyze the trend of the incidence and mortality of liver cancer in China from 2000 to 2019, providing scientific reference for the formulation of prevention and treatment strategies for liver cancer. Methods The information of the incidence and mortality of liver cancer in China from 2000 to 2019 was collected from the Global Health Data Exchange (GHDx) Database. The average annual percent change (AAPC) and annual percent change (APC) were used to describe the trends of the incidence and mortality of liver cancer for the entire population, different sex and different age by using the JoinPoint regression model. Results From 2000 to 2019, the total number of incidence and mortality of liver cancer in China were 4,322,652 cases and 4,093,855 cases, respectively. The standardized incidence rate and mortality rate were 11.31/105 and 9.68/105, respectively. The incidence rate of liver cancer in China showed a downward trend from 2000 to 2019 (AAPC=-2.11%), namely, a decline trend in 2000-2002 and 2002—2005, with APC of -10.55% and -15.45%, respectively, and a slight upward trend in 2005—2010 and 2010—2019, with APC of 0.44% and 3.39%, respectively. The incidence rate of both male and female showed a downward trend (AAPC=-1.95%, -2.43%). The mortality rate of liver cancer in China from 2000 to 2019 showed a decreased trend (AAPC=-2.41%), a decline trend during 2000—2005 with APC of -13.52% and a slight upward trend in 2005—2012 and 2012—2019, with APC of 0.18% and 3.64%, respectively. The mortality rate of both male and female showed a downward trend (AAPC=-2.34%, -2.60%). The age⁃specific incidence rate and mortality rate of liver cancer in China increased with the increase of age (AAPC= 5.94%, 7.10%). The age⁃specific incidence rate of liver cancer for male increased rapidly in 10-40 years old and decreased after 80 years old, while it increased overall for female. The age⁃specific mortality rate of liver cancer for male increased rapidly in 5-10 years old, and for female it increased with the increase of age. Conclusions From 2000 to 2019, the incidence rate and mortality rate of liver cancer in China both show overall downward trend. The incidence rate and mortality rate of male are higher than those of female, and increased with the increase of age. The male and elderly population are the key focus groups for liver cancer. Related Articles | Metrics

Select

Effects of high sodium diet on the burden of gastric cancer in Chinese residents and a trend analysis,1990—2019 NIU Shengli, LIU Bowei 2024, 16 (2):  186-192.  doi: 10.3969/j.issn.1674-5671.2024.02.08 Abstract ( 197 )   PDF   Save Objective To analyze the effects of high sodium diet on the burden of gastric cancer in China and their developing trends, and to provide reference for the optimization of prevention and treatment strategies for high⁃risk populations of gastriv cancer．Methods Based on the data of global burden of disease study 2019 (GBD 2019), the Joinpoint regression model was used to analyze the mortality rate and disability⁃adjusted life⁃years (DALYs) rate of gastric cancer caused by high sodium diet in China from 1990 to 2019. The average annual percent change (AAPC) and 95% confidence interval (CI) were used to represent the change in composition ratio between adjacent years. Results The death rate and crude mortality rate of gastric cancer caused by high sodium diet among Chinese residents increased from 27 226 cases (accounted for 8.913% of the total death of gastric cancer in China) and 2.300/105 in 1990 to 37 131 cases (accounted for 8.808% of the total deaths of gastric cancer in China) and 2.611/105 in 2019, whereas the DALYs rate decreased from 62.048/105 to 61.434/105. The standardized mortality rate of gastric cancer caused by high sodium diet among Chinese residents decreased by 1.716% year by year, with 1.221% for males and 2.661% for females (all P<0.001) from 1990 to 2019. The standardized DALYs rate decreased by 2.005% year by year, with 1.495% for males and 3.067% for females. The DALYs rate in all age groups showed a downward trend (all P<0.001), and the rate of DALYs decreased most rapidly in the age group of 55-59 (AAPC=-2.547%), and slowly in the age group of 80 and above (AAPC=-0.702%). The standardized DALYs rate of stomach cancer caused by high sodium diet among Chinese residents decreased year by year. The rate of decline was higher than that of low and medium social demographic index (SDI) countries or regions (AAPC=-1.209%, -1.119%), but lower than the global average and the average level of high, medium and medium SDI countries or regions (AAPC=-2.094%, -3.166%, -2.361%, -2.090%). Conclusions The burden of gastric cancer caused by high sodium diet among Chinese residents has decreased year by year, but still on a high level; the level of male are higher than that of female, The elderly male population is the key intervention group, and dietary salt reduction intervention should be strengthened to reduce the burden of gastric cancer. Related Articles | Metrics

Select

Screening and diagnostic efficacy evaluation of risk miRNAs during the development of gastric cancer: a multicenter study MA Fuchao, LIU Aiquan, XIE Weishun, SHEN Yanhua, FENG Jie, JIANG Qi, GE Lianying 2024, 16 (2):  193-199.  doi: 10.3969/j.issn.1674-5671.2024.02.09 Abstract ( 114 )   PDF   Save Objective To explore the risk miRNAs during the development of gastric cancer, providing the evidence for early gastric cancer identification in upper gastrointestinal opportunistic screening. Methods The patients who underwent opportunistic screening population for upper gastrointestinal cancer in the Guangxi Medical University Cancer Hospital, the Affiliated Hospital of Youjiang Medical University for Nationalities, and Guilin People's Hospital from June 2021 to August 2023 were enrolled. A total of 107 healthy individuals, 71 patients with early gastric cancer, and 97 patients with advanced gastric cancer were selected. The differential expression of miRNAs was screened by using transcriptome sequencing, and the differential expression of miRNAs was validated by RT⁃qPCR in prospective blood samples of the 3 prospective groups. The diagnostic efficacy of miRNAs was evaluated by using receiver operating characteristic (ROC) curves. Results The differential gene analysis by transcriptome sequencing screened out 6 differentially expressed miRNAs in the development of gastric cancer development, including miR⁃3176, miR⁃885⁃5p, miR⁃203a⁃3p, miR⁃452⁃5p, miR⁃223⁃3p, and miR⁃219a⁃2⁃3p. RT⁃qPCR results showed that miRNA⁃452⁃5p was up⁃regulated in both the early gastric cancer and the advanced gastric cancer (all P<0.001). The ROC curves indicated that the area under the curve (AUC) of miRNA⁃452⁃5p for diagnosing early gastric cancer and advanced gastric cancer were 0.900 and 0.975, respectively. The AUC for distinguishing early gastric cancer and advanced gastric cancer was 0.843. Conclusions miRNA⁃452⁃5p demonstrates a good diagnostic efficacy in early gastric cancer, and may serve as a potential biomarker for the diagnosis of early gastric cancer by liquid biopsy. Related Articles | Metrics

Select

Metabolic level of serum acetyl-carnitine in esophageal squamous cell carcinoma and its diagnostic value YAO Qingchun, WU Longjunyu, YE Chunhua, LI Yuandong, ZHANG Chunyan 2024, 16 (2):  198-204.  doi: 10.3969/j.issn.1674-5671.2024.02.10 Abstract ( 136 )   PDF   Save Objective To investigate the diagnostic values of L⁃carnitine and acetyl⁃carnitine (ACar 2: 0) in esophageal squamous cell carcinoma (ESCC). Methods The serum of 31 ESCC patients from Guangxi Medical University Cancer Hospital from April 2022 to October 2022 were collected and 30 healthy volunteers during the same period were recruited. Ultra⁃high performance liquid chromatography and quadrupole time⁃of⁃flight mass spectrometry (UHPLC⁃QTOF⁃MS/MS) was used to targetedly analyze the serum metabolic changes of L⁃carnitine and acetyl⁃carnitine. The diagnostic efficiency was evaluated by receiver operating characteristic (ROC) curve. Results Compared with the case in healthy controls, there was no significant difference in serum carnitine level in ESCC patients (P=0.149), and the levels of two acetyl⁃carnitine isomers (ACar 2∶0 isomer1 and ACar 2∶0 isomer 2) were increased (both P<0.001). Multivariable analysis showed that ACar 2∶0 isomer 1 >0.0163 μmol/L (OR=19.456, 95%CI: 1.971-192.104, P=0.011) and ACar 2∶0 isomer 2 >0.0148 μmol/L (OR=7.720, 95%CI: 1.047-56.915, P=0.045) were the risk factors for ESCC, while L⁃carnitine (OR=1.310, 95%CI: 0.051-33.951, P=0.871) was not significantly associated with ESCC. The two acetyl⁃carnitine isomers had a good ability to distinguish between ESCC and healthy controls. The area under curve (AUC), sensitivity and specificity of ACar 2∶0 isomer 1 in the diagnosis of ESCC were 0.957, 0.900 and 0.862, respectively. The AUC, sensitivity and specificity of ACar 2∶0 isomer 2 in the diagnosis of ESCC were 0.901, 0.867 and 0.821, respectively. The AUC, sensitivity and specificity of combining ACar 2∶0 isomer 1 and ACar 2∶0 isomer 2 in the diagnosis of ESCC were 0.952, 0.867 and 0.889, respectively. Conclusions Serum acetylcarnitine level increases in ESCC, showing a good efficacy in the diagnosis of ESCC, and may become a potential diagnostic marker. Related Articles | Metrics

Select

Characterization of CD45+CD326+ double-positive cells and their role in the prognostic pre?diction of bladder cancer LIU Hui, MO Han, FENG Chao, XIE Yuanliang, WANG Qiuyan, LI Tianyu 2024, 16 (2):  205-214.  doi: 10.3969/j.issn.1674-5671.2024.02.11 Abstract ( 145 )   PDF   Save Objective To investigate the effect of CD45+CD326+ double positive cells (DPCs) on the prognosis of bladder cancer (BLCA), to construct a scoring system for bladder cancer DPCs⁃related genes, and to explore the characteristics of tumor microenvironment in bladder cancer patients with different DPCs scores. Methods  Single⁃cell sequencing technology was used to analyze the molecular characteristics of DPCs, and mass cytometry was used to analyze the heterogeneity of the tumor microenvironment in patients with high and low proportions of DPCs. Based on the TCGA⁃BLCA cohort, a scoring system was constructed according to the characteristic genes of DPCs and validated in the GSE13507 cohort and the GSE32894 cohort. Results  The prognosis of bladder cancer patients in the high DPCs proportion group was worse than that of patients in the low DPCs proportion group, the tumor microenvironment of patients in the high proportion and low proportion group was heterogeneous, and the immune cells and tumor cells of patients in the low DPCs proportion group had higher expression levels of immune checkpoints, co⁃inhibitors and coactivators (all P<0.05). A scoring system for bladder cancer with 9 DPCS⁃related genes was constructed based on TCGA⁃BLCA cohort (APOBEC3G, CD96, CLEC2D, GNG2, GNLY, IL32, PSMB9, RORA, SKAP1). The results of TCGA⁃BLCA cohort, GSE13507 cohort and GSE32894 cohort showed that the overall survival of bladder cancer patients in the high DPCs score group was significantly shorter than that of patients in the low DPCs score group (all P<0.01), and the signaling pathways such as immunosuppression and estrogen were significantly enriched in the high⁃risk score group. Conclusions  DPCs are closely related to the poor prognosis of bladder cancer, and the model based on the characteristic gene of DPCs can accurately predict the clinical prognosis of bladder cancer patients. Related Articles | Metrics

Select

Analysis of prognostic factors for patients with mismatch repair?proficient advanced colorectal cancer treated by immunotherapy combined with targeted therapy and its prediction nomogram construction LI Ting, LI Qian, LI Yongqiang, LIAO Xiaoli 2024, 16 (2):  215-222.  doi: 10.3969/j.issn.1674-5671.2024.02.12 Abstract ( 141 )   PDF   Save Objective To investigate the prognostic factors affecting immunotherapy combined with targeted therapy for mismatch repair⁃proficient (pMMR) advanced colorectal cancer (CRC) and to establish a nomogram prediction model. Methods The clinical data of patients with pMMR advanced CRC who received immunotherapy combined with targeted therapy at the end line of the Guangxi Medical University Cancer Hospital from January 2020 to January 2023 were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify the factors affecting prognosis. The nomogram models were constructed to predict progress⁃free survival (PFS) and overall survival (OS). Receiver operating characteristic (ROC), consistency index (C⁃index) and calibration curve were used to evaluate the performance of the model. The scores of nomogram prediction were calculated, and the patients were divided into the high⁃risk group and the low⁃risk group by X⁃tile software. Kaplan⁃Meier curve was drawn and Log⁃rank test was conducted to compare the survival differences between the two groups. Results A total of 116 patients were included in this study. Cox regression analysis showed that body mass index (BMI)≥25 kg/m2 was an independent protective factor for OS (HR=0.431, 95%CI: 0.187-0.990), while the cancer⁃inflammation prognostic index (CIPI)≥828.8 was an independent risk factor (HR=1.820, 95%CI: 1.012-3.271). The carcinoembryonic antigen (CEA)>5 ng/mL (HR=2.448, 95%CI: 1.121-5.345) and systematic immune⁃inflammation index (SII)≥663.9 (HR=2.730, 95%CI: 1.205-6.183) were independent risk factors for PFS. In the PFS nomogram model, the C⁃index of the training set and the validation set were 0.625 and 0.601, respectively. The AUCs of the training set at 3, 6, and 12 months were 0.666, 0.639, and 0.811, respectively, and those of the validation set were 0.696, 0.647, and 0.588, respectively. In the OS nomogram model, the C⁃index of the training set and the validation set were 0.663 and 0.662, respectively. The AUCs of the training set at 6 and 12 months were 0.689 and 0.761, respectively, and those of the validation set were 0.726 and 0.691, respectively. The OS rate curve in the calibration plot was fitted well with the 45°diagonal, indicating that the nomogram model had good discrimination. The Log⁃rank test showed that the PFS rate and OS rate of the low⁃risk group were higher than those of the high⁃risk group ( all P<0.001 ). Conclusions The nomogram model based on prognostic factors such as BMI, CIPI, SII and CEA can effectively predict the prognosis of patients with CRC immunotherapy. BMI, CIPI, SII and CEA may be potential markers for evaluating the prognosis of CRC immunotherapy. Related Articles | Metrics

Select

Summary of the best evidence for non?drug prevention and management of sleep disorders in breast cancer survivors LEI Lei, XUE Xiaojing, SHI Qiulin, WANG Xiaoyan, FENG Gang, YANG Lijuan, JIANG Yuan, LIU Ran 2024, 16 (2):  223-229.  doi: 10.3969/j.issn.1674-5671.2024.02.13 Abstract ( 153 )   PDF   Save Objective To screen, extract and summarize the best evidence related to non⁃drug prevention and management of sleep disorders in breast cancer survivors, providing a relevant practical basis for sleep management in breast cancer survivors. Methods The PIPOST model was used to construct evidence⁃based questions. According to the "6S" model of evidence⁃based search resources, computer⁃aided literature search was conducted on PubMed, BMJ Best Practice, JBI Evidence⁃Based Health Care Center, NICE, Web of Science, American Society of Clinical Oncology (ASCO), CNKI, and Wanfang Database. The search content included clinical guidelines, expert consensus, systematic evaluation, randomized controlled trials, clinical decision⁃making, and evidence summary. Results A total of 13 references were included, including 2 clinical guidelines, 2 expert consensus, 3 systematic reviews, and 6 randomized controlled trials; 27 pieces of evidence were summarized with 6 dimensions, i.e., sleep disorder screening and evaluation, sports activity recommendations, mindfulness training treatment, cognitive behavioral intervention, traditional Chinese medicine treatment, and sleep hygiene and health education. Conclusions The 27 best evidences summarized in this study provides a relevant practical basis for sleep management of breast cancer survivors, and it is helpful to combine the evidence with clinical practice in developing systematic, comprehensive and individualized sleep management programs. Related Articles | Metrics

Select

A survival report of 78,046 patients with malignant tumor from a hospital?based cancer registry database CHEN Lijun, LIANG Xiumei, WU Yun, LU Xiangning, XIE Ganglin, YANG Zhijun 2024, 16 (2):  229-237.  doi: 10.3969/j.issn.1674-5671.2024.02.14 Abstract ( 114 )   PDF   Save Objective To reflect current cancer treatment effect with real world data based on the follow⁃up data of patients with malignant tumors from a hospital⁃based cancer registry database. Methods The hospitalized patients with malignant tumors diagnosed in the Guangxi Medical University Cancer Hospital from January 1 of 2011 and December 31 of 2020 were enrolled, and a total of 78,046 cases with 17 types of malignant tumors had the follow⁃up data meeting the quality requirements. The survival follow⁃up information was collected from the disease management system records and by telephone visits, and the follow⁃up statistics were conducted as of June 30, 2023. Life table was use to evaluate the 1⁃year, 3⁃year and 5⁃year overall survival (OS) rates of each disease, the survivals of patients with respect to gender, age group, nationality, clinical stages and the first treatment time were analyze. Results The top 5 cancers were liver cancer (14,672 cases), lung cancer (10,878 cases), female breast cancer (9,430 cases), colorectal cancer (6,895 cases) and cervical cancer (6,250 cases). The 1⁃year, 3 year and 5⁃year OS rates of patients with 17 typs of malignant tumors were 76.3%、58.6% and 51.4%, respectively. The 5⁃year OS rate of male patients was lower than that of female patients (39.9% vs 63.1%). The overall trend of OS for each cancer species decreased with increase of age, and the 5⁃year OS rates were 64.0%, 59.6%, 52.7%, 44.9%, and 35.7% for the age groups of ≤44, 45-54, 55-64, 65-74, and ≥75, respectively. Compared with those in the period of 2011—2015, the 5⁃year OS rates of patients with liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer and lymphoma were significantly higher (all P<0.05) during 2016—2020. There was significant difference in survival among patients with different clinical stages of malignant tumors (all P<0.01), and the 5⁃year OS rate of patients with stageⅠ-Ⅱ was higher than that of patients with stage Ⅲ-Ⅳ (82.2% vs 43.4%).The 5⁃year OS rate of patients with liver cancer, lung cancer, female breast cancer, nasopharyngeal carcinoma, colorectal cancer and cervical cancer in Zhuang nationality was significantly lower than that in Han nationality (all P<0.05). Conclusions Liver cancer and lung cancer are the main types of cancer to be treated, and more than 50% of patients with malignant tumors can survive for more than 5 years. The survival status of patients with malignant tumors is significantly different with respect to tumor type, age, gender and nationality. The standardized, innovative, multidisciplinary and precise clinical treatment and the early diagnosis and treatment of cancer should be continuously implemented to further improve the survival of patients. Related Articles | Metrics

Select

Effect of m6A modification on ovarian cancer and its value as a potential therapeutic target LONG Yuhao, ZHENG Bohao, ZHOU Shengtao 2024, 16 (2):  238-242.  doi: 10.3969/j.issn.1674-5671.2024.02.15 Abstract ( 153 )   PDF   Save Related Articles | Metrics

Select

Advances in immune checkpoint inhibitor therapy for advanced non?small cell lung cancer LIU Bin, GUO Shuliang 2024, 16 (2):  243-248.  doi: 10.3969/j.issn.1674-5671.2024.02.16 Abstract ( 214 )   PDF   Save Related Articles | Metrics

Select

Role of protein phosphatase 4 catalytic subunit in tumor progression XIAN Shinan, MO Yingxi, WANG Shan, YANG Yiping, ZHANG Qingyun 2024, 16 (2):  249-254.  doi: 10.3969/j.issn.1674-5671.2024.02.17 Abstract ( 135 )   PDF   Save Related Articles | Metrics

Select

Progress in the application of patient?reported outcomes in tumor immunotherapy WANG Huilin, JIANG Wei, YU Qitao 2024, 16 (2):  255-260.  doi: 10.3969/j.issn.1674-5671.2024.02.18 Abstract ( 145 )   PDF   Save Related Articles | Metrics